Jeffrey M. Leiden
2015 - Vertex Pharmaceuticals
In 2015, Jeffrey M. Leiden earned a total compensation of $28.1M as Chairman, President & CEO at Vertex Pharmaceuticals, a 23% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $3,463,200 |
|---|---|
| Option Awards | $16,286,939 |
| Salary | $1,297,692 |
| Stock Awards | $7,038,885 |
| Other | $13,110 |
| Total | $28,099,826 |
Leiden received $16.3M in option awards, accounting for 58% of the total pay in 2015.
Leiden also received $3.5M in non-equity incentive plan, $1.3M in salary, $7M in stock awards and $13.1K in other compensation.
Rankings
In 2015, Jeffrey M. Leiden's compensation ranked 43rd out of 13,638 executives tracked by ExecPay. In other words, Leiden earned more than 99.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 43 out of 13,638 | 100th |
Division Manufacturing | 13 out of 5,190 | 100th |
Major group Chemicals And Allied Products | 8 out of 1,854 | 100th |
Industry group Drugs | 7 out of 1,528 | 100th |
Industry Pharmaceutical Preparations | 6 out of 1,182 | 100th |
Source: SEC filing on April 28, 2017.
Leiden's colleagues
We found four more compensation records of executives who worked with Jeffrey M. Leiden at Vertex Pharmaceuticals in 2015.